The effect of topical betamethasone and oral melatonin in the treatment of atopic dermatitis

Phase 3

Recruiting

• Conditions: Atopic dermatitis.; Atopic dermatitis, unspecified; L20.9

• Registration Number: IRCT20200825048515N23
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age between 18-65 years
Satisfaction to participate in the study

Exclusion Criteria

Extent of involvement less than 2% or more than 30% of the body surface
Skin problems other than atopic dermatitis
Severe systemic diseases (kidney disease, diabetes, uncontrolled hypertension, and other chronic diseases)
Use of systemic medications for atopic dermatitis 4 weeks before the start of the study
Use of topical medications for atopic dermatitis 2 weeks before the start of the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Scaling severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD).;Blister severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD).;Redness severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD).;Dermatitis severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD).